Evaluating the effectiveness of laser treatment for glaucoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with open-angle glaucoma who are scheduled to receive direct selective laser trabeculoplasty (DSLT) treatment. The study will monitor the impact of DSLT on intraocular pressure (IOP) over a 12-month period, with follow-up visits at one week, one month, three months, six months, and twelve months post-treatment. The treatment involves applying 120 laser pulses using the Voyager DSLT system to reduce IOP in patients who are not on hypotensive medication. The study aims to gather data on the efficacy of this laser treatment in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria: • Age over 18 years

• Diagnosis of open angle glaucoma in eye study and scheduled for both eyes being treated after bilateral laser indication. The diagnosis of glaucoma will be based on the presence of optic nerve damage that is compatible with glaucoma in the absence of any other cause that could have produced this damage, with an IOP value\>21 mmHg.

Exclusion Criteria:

* Patients diagnosed with uveitis, angle closure or congenital glaucoma.
* Presence of anterior peripheral synechiae
* Patients unable to complete three, six- and 12-months follow-up.
* Patients having undergone intraocular surgery, save for uneventful phacoemulsification (performed at least 6 months prior to inclusion)

Where it's running

• Clínica Rementería
  Madrid, Madrid, Spain Recruiting

Study contacts

• Study coordinator: Inés Contreras
• Email: contreras@clinicarementeria.es
• Phone: +34913083838

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Balance training for people with glaucoma

  A randomized study tests whether a structured eight-week balance program helps adults with glaucoma improve balance, reduce fall risk, and lessen fear of falling.

  Recruiting Kanuni Sultan Suleyman Training and Research Hospital · Küçükçekmece, Istanbul · NCT07910955

• Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma

  In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.

  Recruiting Phase 4 Indiana University · Bloomington, Indiana · NCT07847073

• Comparison of FT-1000 non-contact tonometry with Goldmann applanation tonometry in glaucoma patients

  This study tests whether the FT-1000 non-contact tonometer gives measurements that agree with the Goldmann applanation tonometer in adults with glaucoma.

  Recruiting Tomey Corporation · Jacksonville, Florida · NCT07804277

• Removing the ripcord from a glaucoma drainage device after 3 months

  This study tests whether removing the ripcord from an implanted glaucoma drainage device changes eye pressure for adults with open-angle glaucoma.

  Recruiting Duke University · Durham, North Carolina · NCT07803536

• Glaucoma and Brain Changes: How Brain Structure and Size See What Glaucoma Is Doing

  This study tests whether glaucoma is linked to broader brain changes by comparing brain MRI and eye health over time in people with glaucoma and matched controls.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07802769

• Long-Term Results After Ab-interno Trabeculotomy for Glaucoma

  This study tests whether ab-interno trabeculotomy with the Trabectome can provide sustained intraocular pressure reduction in glaucoma patients who had the procedure between 2019 and 2021.

  Recruiting Wuerzburg University Hospital · Würzburg, Bavaria · NCT07780916

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.